The role of everolimus in metastatic breast cancer and possibilities of moving forward-a narrative review.

ABSTRACT:

Background and objective

In hormone-receptor-positive (HR⁺) and human epidermal growth factor receptor 2-negative (HER2^-) metastatic breast cancer endocrine-based therapies are preferred over chemotherapy. One of the treatment options is the combination of everolimus with exemestane or other endocrine drug in later lines mainly based on progression-free survival (PFS) results of the phase 3 BOLERO-2 trial. Altogether, clinical trials did not prove an overall survival (OS) benefit and considerable side effects hampered its application in the day-by-day practice. In recent years CDK4/6-inhibitors became a first-choice combination partner to the endocrine treatment, everolimus still has a place within the treatment armamentarium. Although everolimus is a targeted

SUBMITTER: Rubovszky G 

PROVIDER: S-EPMC11304436 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature